David J. McConkey, Ph.D.

Director, Johns Hopkins Greenberg Bladder Cancer Institute
Professor of Urology, Oncology

Johns Hopkins Medical Institutions
Office: (410) 502-1807


Research in Dr. McConkey’s laboratory is focused on defining the molecular mechanisms involved in bladder cancer progression and developing novel therapies for muscle-invasive disease. In current efforts he is using whole genome approaches to define the molecular heterogeneity in muscle-invasive bladder cancers and defining the molecular mechanisms that dictate sensitivity and resistance to conventional cisplatin-based combination chemotherapy, EGFR and FGFR inhibitors, and proteasome inhibitors. He is Chair for Translational Medicine in the Southwest Oncology Group’s GU Subcommittee and has been actively involved in TCGA’s Bladder Cancer Analysis Working Group.



Education and Training

1982-1986 Brown University, Providence, RI, BA, Biochemistry and American History Doctoral/Graduate 1986-1989 Karolinska Institute, Stockholm, Sweden, PhD, Biochemical Toxicology
1990-1993 Laboratory of Immunobiology, Dana-Farber Cancer Institute, and Department of Pathology, Harvard Medical School, Boston, MA, Ellis L. Reinherz, M.D.

Professional Experience

1993-1999 Assistant Professor, Department of Cell Biology, the University of Texas M. D. Anderson Cancer Center, Houston, TX
1999-2007 Associate Professor, Department of Cancer Biology, the University of Texas M. D. Anderson Cancer Center, Houston, TX
2007-2016 Professor, Departments of Urology and Cancer Biology, the University of Texas MD Anderson Cancer Center, Houston, TX
2007-2016 Director of Urological Research, The University of Texas MD Anderson Cancer Center, Houston, TX
2016-present Director, Johns Hopkins Greenberg Bladder Cancer Institute
2016-present Professor of Urology, The James Buchanan Brady Urological Institute at Johns Hopkins


 Free access to abstracts at PubMed


Original Research

  1. McConkey DJ, Crankshaw DL, Holtzman JL. Glucagon activation of the thiol:protein disulfide oxidoreductase in isolated, rat, hepatic microsomes. Life Sci. 1986:38:2139-2143. PMID: 3520201.
  2. Moore GA, McConkey DJ, Kass GE, O'Brien PJ, Orrenius S. 2,5-Di(tert-butyl)-1,4-benzohydroquinone--a novel inhibitor of liver microsomal Ca2+ sequestration. FEBS Lett. 1987:224:331-336. PMID: 2961610.
  3. McConkey DJ, Hartzell P, Nicotera P, Wyllie AH, Orrenius S. Stimulation of endogenous endonuclease activity in hepatocytes exposed to oxidative stress. Toxicol Lett. 1988:42:123-230. PMID: 2841775.
  4. McConkey DJ, Hartzell P, Duddy SK, Hakansson H, Orrenius S. 2,3,7,8-Tetrachlorodibenzo-p-dioxin kills immature thymocytes by Ca2+-mediated endonuclease activation. Science. 1988:242:256-259. PMID: 3262923.
  5. Nicotera P, McConkey DJ, Svensson SA, Bellomo G, Orrenius S. Correlation between cytosolic Ca2+ concentration and cytotoxicity in hepatocytes exposed to oxidative stress. Toxicology. 1988:52:55-63. PMID: 3188034.
  6. McConkey DJ, Nicotera P, Hartzell P, Bellomo G, Wyllie AH, Orrenius S. Glucocorticoids activate a suicide process in thymocytes through an elevation of cytosolic Ca2+ concentration. Arch Biochem Biophys. 1989:269:365-370. PMID: 2537063.
  7. Jones DP, McConkey DJ, Nicotera P, Orrenius S. Calcium-activated DNA fragmentation in rat liver nuclei. J Biol Chem. 1989:264:6398-6403. PMID: 2703497.
  8. McConkey DJ, Orrenius S. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) kills glucocorticoid-sensitive thymocytes in vivo. Biochem Biophys Res Commun. 1989:160:1003-1008. PMID: 2543382.
  9. McConkey DJ, Hartzell P, Nicotera P, Orrenius S. Calcium-activated DNA fragmentation kills immature thymocytes. Faseb J. 1989:3:1843-1849. PMID: 2497041.
  10. McConkey DJ, Hartzell P, Jondal M, Orrenius S. Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that stimulate protein kinase C. J Biol Chem. 1989:264:13399-13402. PMID: 2503500.
  11. McConkey DJ, Hartzell P, Amador-Perez JF, Orrenius S, Jondal M. Calcium-dependent killing of immature thymocytes by stimulation via the CD3/T cell receptor complex. J Immunol. 1989:143:1801-1806. PMID: 2528581.
  12. Chow SC, McConkey DJ, Orrenius S, Jondal M. Quantitation of DNA fragmentation using fiberglass filters. Anal Biochem. 1989:183:42-45. PMID: 2619047.
  13. Nicotera P, McConkey DJ, Jones DP, Orrenius S. ATP stimulates Ca2+ uptake and increases the free Ca2+ concentration in isolated rat liver nuclei. Proc Natl Acad Sci U S A. 1989:86:453-457. PMID: 2911591.
  14. McConkey DJ, Hartzell P, Chow SC, Orrenius S, Jondal M. Interleukin 1 inhibits T cell receptor-mediated apoptosis in immature thymocytes. J Biol Chem. 1990:265:3009-3011. PMID: 2105939.
  15. McConkey DJ, Hartzell P, Orrenius S. Rapid turnover of endogenous endonuclease activity in thymocytes: effects of inhibitors of macromolecular synthesis. Arch Biochem Biophys. 1990:278:284-287. PMID: 2157360.
  16. McConkey DJ, Chow SC, Orrenius S, Jondal M. NK cell-induced cytotoxicity is dependent on a Ca2+ increase in the target. Faseb J. 1990:4:2661-2664. PMID: 2347464.
  17. McConkey DJ, Orrenius S, Jondal M. Agents that elevate cAMP stimulate DNA fragmentation in thymocytes. J Immunol. 1990:145:1227-1230. PMID: 2166110.
  18. Perotti M, Toddei F, Mirabelli F, Vairetti M, Bellomo G, McConkey DJ, Orrenius S. Calcium-dependent DNA fragmentation in human synovial cells exposed to cold shock. FEBS Lett. 1990:259:331-334. PMID: 2152884.
  19. McConkey DJ, Aguilar-Santelises M, Hartzell P, Eriksson I, Mellstedt H, Orrenius S, Jondal M. Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells. J Immunol. 1991:146:1072-1076. PMID: 1988495.
  20. Bauer A, McConkey DJ, Howard FD, Clayton LK, Novick D, Koyasu S, Reinherz EL. Differential signal transduction via T-cell receptor CD3 zeta 2, CD3 zeta-eta, and CD3 eta 2 isoforms. Proc Natl Acad Sci U S. 1991:88:3842-3846. PMCID: PMC51549.
  21. Moingeon P, Lucich JL, McConkey DJ, Letourneur F, Malissen B, Kochan J, Chang HC, Rodewald HR, Reinherz EL. CD3 zeta dependence of the CD2 pathway of activation in T lymphocytes and natural killer cells. Proc Natl Acad Sci U S A. 1992:89:1492-1496. PMCID: PMID48477.
  22. Koyasu S, McConkey DJ, Clayton LK, Abraham S, Yandava B, Katagiri T, Moingeon P, Yamamoto T, Reinherz EL. Phosphorylation of multiple CD3 zeta tyrosine residues leads to formation of pp21 in vitro and in vivo. Structural changes upon T cell receptor stimulation. J Biol Chem. 1992:267:3375-3381. PMID: 1531339.
  23. Howard FD, Moingeon P, Moebius U, McConkey DJ, Yandava B, Gennert TE, Reinherz EL. The CD3 zeta cytoplasmic domain mediates CD2-induced T cell activation. J Exp Med. 1992:176:139-145. PMCID: PMC2119282.
  24. Hussey RE, Clayron LK, Diener A, McConkey DJ, Howard FD, Rodewald HR, D’Adamio L, Dallenbach F, Stein H, Schmidt EV, Koyasu S, Reinherz EL. Overexpression of CD3 eta during thymic development does not alter the negative selection process. J Immunol. 1993:150:1183-1194. PMID: 8094404.
  25. McConkey DJ, Orrenius S, Okret S, Jondal M. Cyclic AMP potentiates glucocorticoid-induced endogenous endonuclease activation in thymocytes. Faseb J. 1993:7:580-585.
  26. Moingeon P, Rodewald HR, McConkey DJ, Mildonian A, Awad K, Reinherz EL. Generation of natural killer cells from both Fc gamma RII/III+ and Fc gamma RII/III-murine fetal liver progenitors. Blood. 1993:82:1453-1462. PMID: 8364197.
  27. Jondal M, Okret S, McConkey DJ. Killing of immature CD4+ CD8+ thymocytes in vivo by anti-CD3 or 5'-(N-ethyl)-carboxamide adenosine is blocked by glucocorticoid receptor antagonist RU-486. Eur J Immunol. 1993:23:1246-1250. PMID: 8099013.
  28. McConkey DJ, Fosdick L, D'Adamio L, Jondal M, Orrenius S. Co-receptor (CD4/CD8) engagement enhances CD3-induced apoptosis in thymocytes. Implications for negative selection. J Immunol. 1994:153:2436-2443. PMID: 8077659.
  29. Fernandez A, Fosdick LJ, Marin MC, Diaz C, McDonnell TJ, Ananthaswamy HN, McConkey DJ. Differential regulation of endogenous endonuclease activation in isolated murine fibroblast nuclei by ras and bcl-2. Oncogene. 1995:10:769-774. PMID: 7862455.
  30. Neamati N, Fernandez A, Wright S, Kiefer J, McConkey DJ. Degradation of lamin B1 precedes oligonucleosomal DNA fragmentation in apoptotic thymocytes and isolated thymocyte nuclei. J Immunol. 1995:154:3788-3795. PMID: 7535814.
  31. Kiefer J, Okret S, Jondal M, McConkey DJ. Functional glucocorticoid receptor expression is required for cAMP-mediated apoptosis in a human leukemic T cell line. J Immunol. 1995:155:4525-4528. PMID: 7594448.
  32. Fernandez A, Kiefer J, Fosdick L, McConkey DJ. Oxygen radical production and thiol depletion are required for Ca(2+)-mediated endogenous endonuclease activation in apoptotic thymocytes. J Immunol. 1995:155:5133-5139. PMID: 7594522.
  33. McConkey DJ, Chandra J, Wright S, Plunkett W, McDonnell TJ, Reed JC, Keating M. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol. 1996:156:2624-2630. PMID: 8786328.
  34. Warren AP, Patel K, McConkey DJ, Palacios R. CD98: a type II transmembrane glycoprotein expressed from the beginning of primitive and definitive hematopoiesis may play a critical role in the development of hematopoietic cells. Blood. 1996:87:3676-3687. PMID: 8611692.
  35. Marin MC, Fernandez A, Bick RJ, Brisbay S, Buja LM, Snuggs M, McConkey DJ, von Eschenbach AC, Keating MJ, McDonnell TJ. Apoptosis suppression by bcl-2 is correlated with the regulation of nuclear and cytosolic Ca2+. Oncogene. 1996:12:2259-2266. PMID: 8649765.
  36. McConkey DJ. Calcium-dependent, interleukin 1-converting enzyme inhibitor-insensitive degradation of lamin B1 and DNA fragmentation in isolated thymocyte nuclei. J Biol Chem. 1996:271:22398-22406. PMID: 8798402.
  37. Trent JC, McConkey DJ, Loughlin SM, Harbison MT, Fernandez A, Ananthaswamy HN. Ras signaling in tumor necrosis factor-induced apoptosis. Embo J. 1996:15:4497-4505. PMCID: PMC452179.
  38. Xie K, Huang S, Wang Y, Beltran PJ, Juang SH, Dong Z, Reed JC, McDonnell TJ, McConkey DJ, Fidler IJ. Bcl-2 protects cells from cytokine-induced nitric-oxide-dependent apoptosis. Cancer Immunol Immunother. 1996:43:109-115. PMID: 8954145.
  39. McConkey DJ, Goodrich D, Bucana C, Klostergaard J. The human retinoblastoma gene product suppresses ceramide-induced apoptosis in human bladder tumor cells. Oncogene. 1996:13:1693-1700. PMID: 8895515.
  40. McConkey DJ, Greene G, Pettaway CA. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res. 1996:56:5594-5599. PMID: 8971161.
  41. Huang S, Luca M, Gutman M, McConkey DJ, Langley KE, Lyman SD, Bar-Eli M. Enforced c-KIT expression renders highly metastatic human melanoma cells suspectible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene. 1996:13:2339-2347. PMID: 8957075.
  42. Gossett R, Kier AB, Schroeder F, McConkey DJ, Fadok V, Amoss MS, Jr. Cycloheximide-induced apoptosis in melanoma cells derived from regressing cutaneous tumours of Sinclair swine. J Comp Pathol. 1996:115:353-372. PMID: 9004078.
  43. Xue Y, Murdjeva M, Okret S, McConkey DJ, Kiuossis D, Jondal M. Inhibition of I-Ad-, but not Db-restricted peptide-induced thymic apoptosis by glucocorticoid receptor antagonist RU486 in T cell receptor transgenic mice. Eur J Immunol. 1996:26:428-434. PMID: 8617314.
  44. Xie K, Wang Y, Huang S, Xu L, Bielenberg D, Salas T, McConkey DJ, Jiang W, Fidler IJ. Nitric oxide-mediated apoptosis of K-1735 melanoma cells is associated with downregulation of Bcl-2. Oncogene. 1997:15:771-779. PMID: 9266963.
  45. Mirkovic N, Voehringer DW, Story MD, McConkey DJ, McDonnell TJ, Meyn RE. Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. Oncogene. 1997:15:1461-1470. PMID: 9333022.
  46. Chandra J, Gilbreath J, Freireich EJ, Kliche KO, Andreeff M, Keating M, McConkey DJ. Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemic lymphocytes. Blood. 1997:90:3673-3681. PMID: 9345052.
  47. Voehringer DW, McConkey DJ, McDonnell TJ, Brisbay S, Meyn RE. Bcl-2 expression causes redistribution of glutathione to the nucleus. Proc Natl Acad Sci U S A. 1998:95:2956-2960.
  48. Jean D, Harbison M, McConkey DJ, Ronai Z, Bar-Eli M. CREB and its associated proteins act as survival factors for human melanoma cells. J Biol Chem. 1998:273:24884-14890. PMID: 9733794.
  49. Bouvet M, Bold RJ, Lee J, Evans DB, Abbruzzese JL, Chiao PJ, McConkey DJ, Chandra J, Chada S, Fang B, Roth JA. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments]. Ann Surg Oncol. 1998:5:681-688. PMID: 9869513.
  50. Chandra J, Niemer I, Gilbreath J, Kliche KO, Andreeff M, Freireich EJ, Keating M, McConkey DJ. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood. 1998:92:4220-4229. PMID: 9834227.
  51. Diaz C, Lee AT, McConkey DJ, Schroit AJ. Phosphatidylserine externalization during differentiation-triggered apoptosis of erythroleukemic cells. Cell Death Differ. 1999:6:218-226. PMID: 10200572.
  52. Bold RJ, Chandra J, McConkey DJ. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol. 1999:6:279-285. doi: 10.1007/s10434-999-0279-x.
  53. Bold RJ, Hess KR, Pearson AS, Grau AM, Sinicrope FA, Jennings M, McConkey DJ, Bucana CD, Cleary KR, Hallin PA, Chiao PJ, Abbruzzese JL, Evans DB. Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. J Gastrointest Surg. 1999:3:263-277. PMID: 10481119.
  54. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, McConkey DJ, McMahon G, Ellis LM. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. 1999:59:5412-5416. PMID: 10554007.
  55. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey DJ, Yung WK, Steck PA. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res. 1999:59:2551-2556. PMID: 10363971.
  56. Watson VE, Hill LL, Owen-Schaub LB, Davis DW, McConkey DJ, Jagannath C, Hunter RL, Jr, Actor JK. Apoptosis in mycobacterium tuberculosis infection in mice exhibiting varied immunopathology. J Pathol. 2000:190:211-220. PMID: 10657021.
  57. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanism. Clin Cancer Res. 2000:6:1936-1948. PMID: 10815919.
  58. Jean D, Tellez C, Huang S, Davis DW, Bruns CJ, McConkey DJ, Hinrichs SH, Bar-Eli M. Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene. 2000:19:2721-2730. PMID: 10851072.
  59. McConkey DJ, Lin Y, Nutt LK, Ozel HZ, Newman RA. Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res. 2000:60:3807-3812. PMID: 10919654.
  60. Multani AS, Ozen M, Narayan S, Kumar V, Chandra J, McConkey DJ, Newman RA, Pathak S. Caspase-dependent apoptosis induced by telomere cleavage and TRF2 loss. Neoplasia. 2000:2:339-345. PMCID: PMC1550291.
  61. Inoue K, Slaton JW, Davis DW, Hicklin DJ, McConkey DJ, Karashima T, Radinsky R, Dinney CP. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res. 2000:6:2635-2643. PMID: 10914704.
  62. Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer. 2000:89:488-499. PMID: 10931447.
  63. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Davis DW, McConkey DJ, Fidler IJ. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res. 2000:60:4959-4967. PMID: 10987313.
  64. Davis DW, Weidner DA, Holian A, McConkey DJ. Nitric oxide-dependent activation of p53 suppresses bleomycin-induced apoptosis in the lung. J Exp Med. 2000:192:857-869. PMCID: PMC2193293.
  65. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R, Dinney CP. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res. 2000:6:4874-4884. PMID: 11156247.
  66. Pathak S, Multani AS, McConkey DJ, Imam AS, Amoss MS, Jr. Spontaneous regression of cutaneous melanoma in sinclair swine is associated with defective telomerase activity and extensive telomere erosion. Int J Oncol. 2000:17:1219-1224. PMID: 11078808.
  67. Ouhtit A, Muller HK, Davis DW, Ullrich SE, McConkey DJ, Ananthaswamy HN. Temporal events in skin injury and the early adaptive responses in ultraviolet-irradiated mouse skin. Am J Pathol. 2000:156:201-207. PMCID: PMC1868641.
  68. Bruns CJ, Shinohara H, Harbison MT, Davis DW, Nelkin G, Killion JJ, McConkey DJ, Dong Z, Fidler IJ. Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages. Cancer Res. 2000:60:2-7. PMID: 10646841.
  69. Shaheen RM, Tseng WW, Davis DW, Liu W, Reinmuth N, Vellagas R, Wieczorek AA, Ogura Y, McConkey DJ, Drazan KE, Bucana CD, McMahon G, Ellis LM. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res. 2001:61:1464-1468. PMID: 11245452.
  70. Liu W, Davis DW, Ramirez K, McConkey DJ, Ellis LM. Endothelial cell apoptosis is inhibited by a soluble factor secreted by human colon cancer cells. Int J Cancer. 2001:92:26-30. PMID: 11279602.
  71. Bold RJ, Virudachalam S, McConkey DJ. BCL2 expression correlates with metastatic potential in pancreatic cancer cell lines. Cancer. 2001:92:1122-1129. PMID: 11571724.
  72. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res. 2001:100:11-17. PMID: 11516199.
  73. Slaton JW, Karashima T, Perrotte P, Inoue K, Kim SJ, Izawa J, Kedar D, McConkey DJ, Millikan R, Sweeney P, Yoshikawa C, Shuin T, Dinney CP. Treatment with low-dose interferon-alpha restore the balance between matrix metalloproteinase-9 and E-cadherin in human transitional cell carcinoma of the bladder. Clin Cancer Res. 2001:7:2840-2853. PMID: 11555602.
  74. Solorzano CC, Jung YD, Bucana CD, McConkey DJ, Gallick GE, McMahon G, Ellis LM. In vivo intracellular signaling as a marker of antiangiogenic activity. Cancer Res. 2001:61:7048-7051. PMID: 11585733.
  75. Cao XX, Mohuiddin I, Ece F, McConkey DJ, Smythe WR. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol. 2001:25:562-568. PMID: 11713097.
  76. Nyormoi O, Wang Z, Doan D, Ruiz M, McConkey DJ, Bar-Eli M. Transcription factor AP-2a is preferentially cleaved by caspase 6 and degraded by proteasome during tumor necrosis factor a-induced apoptosis in breast cancer cells. Mol Cell Biol. 2001:21:4856-4867. PMCID: PMC87191.
  77. Nutt LK, Pataer A, Pahler J, Fang B, Roth J, McConkey DJ, Swisher SG. Bax and Bak promote apoptosis by modulating endoplasmic reticular and mitochondrial Ca2+ stores. J Biol Chem. 2002:277:9219-9225. PMID: 11741880.
  78. Bondar VM, McConkey DJ. Anoikis is regulated by BCL-2-independent pathways in human prostate carcinoma cells. Prostate. 2002:51:42-49.
  79. Agui T, McConkey DJ, Tanigawa N. Comparative study of various biological parameters, including expression of survivin, between primary and metastatic human colonic adenocarcinomas. Anticancer Res. 2002:22:1769-1776. PMID: 12168867.
  80. Santamaria AB, Davis DW, Nghiem DX, McConkey DJ, Ullrich SE, Kapoor M, Lozano G, Ananthaswamy HN. p53 and Fas ligand are required for psoralen and UVA-induced apoptosis in mouse epidermal cells. Cell Death Differ. 2002:9:549-560. PMID: 11973613.
  81. Jung YD, Fan F, McConkey DJ, Jean ME, Liu W, Reinmuth N, Stoeltzing O, Ahmad SA, Parikh AA, Mukaida N, Ellis LM. Role of P38 MAPK, AP-1, and NF-kappaB in interleukin-1beta-induced IL-8 expression in human vascular smooth muscle cells. Cytokine. 2002:18:206-213. PMID: 12126643.
  82. Nutt LK, Chandra J, Pataer A, Fang B, Roth JA, Swisher SG, O'Neil RG, McConkey DJ. Bax-mediated Ca2+ mobilization promotes cytochrome c release during apoptosis. J Biol Chem. 2002:277:20301-20308. PMID: 11909872.
  83. Guo Z, Clydesdale G, Cheng J, Kim K, Gan L, McConkey DJ, Ullrich SE, Zhuang Y, Su B. Disruption of Mekk2 in mice reveals an unexpected role for MEKK2 in modulating T-cell receptor signal transduction. Mol Cell Biol. 2002:22:5761-5768. PMCID: PMC133978.
  84. Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002:20:3804-3814. PMID: 12228200.
  85. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2002:20:3792-3803. PMID: 12228199.
  86. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2002:1:989-997. PMID: 12481421.
  87. Windham TC, Parikh NU, Siwak DR, Summy JM, McConkey DJ, Kraker AJ, Gallick GE. Src activation regulates anoikis in human colon tumor cell lines. Oncogene. 2002:21:7797-7807. PMID: 12420216.
  88. Cao XX, Mohuiddin I, Chada S, Mhashilkar AM, Ozvaran MK, McConkey DJ, Miller SD, Daniel JC, Smythe WR. Adenoviral transfer of mda-7 leads to BAX up-regulation and apoptosis in mesothelioma cells, and is abrogated by over-expression of BCL-XL. Mol Med. 2002:8:869-876.
  89. Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, Elliott P, Adams J, McConkey DJ. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther. 2002:1:1243-1253.
  90. Termuhlen PM, Sweeney-Gotsch BM, Berman RS, Ellis LM, Bucana C, Shen Y, Cleary KR, McConkey DJ. Increased apoptosis in metastatic human colonic adenocarcinomas. Cancer Biol Ther. 2002:1:58-63.
  91. Davis DW, Buchholz TA, Hess KR, Sahin AA, Valero V, McConkey DJ. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res. 2003:9:955-960.
  92. Karashima T, Sweeney P, Kamat A, Huang S, Kim SJ, Bar-Eli M, McConkey DJ, Dinney CP. Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res. 2003:9:2786-2797.
  93. Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez C, Yang XD, Gudas JM, McConkey DJ, Bar-Eli M. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res. 2003:9:3167-3175.
  94. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther. 2003:2:835-843.
  95. Pahler JC, Ruiz S, Niemer I, Calvert LR, Andreeff M, Keating M, Faderl S, McConkey DJ. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res. 2003:9:4570-4577.
  96. Williams SA, McConkey DJ. The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res. 2003:63:7338-7344.
  97. Zhang X, Multani AS, Zhou JH, Shay JW, McConkey DJ, Dong L, Kim CS, Rosser CJ, Pathak S, Benedict WF. Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cells. Cancer Res. 2003:63:760-765.
  98. Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, Tucker SL, Pusztai L, Cristofanilli M, Esteva FJ, Hortobagyi GN, Sahin AA. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J. 2003:9:33-41.
  99. Yang P, Collin P, Madden T, Chan D, Sweeney-Gotsch B, McConkey DJ, Newman RA. Inhibition of proliferation of PC3 cells by the branched-chain fatty acid, 12-methyltetradecanoic acid, is associated with inhibition of 5-lipoxygenase. Prostate. 2003:55:281-291.
  100. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, McConkey DJ. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther. 2004:3:279-290.
  101. Raut CP, Takamori RK, Davis DW, Sweeney-Gotsch B, O'Reilly MS, McConkey DJ. Direct effects of recombinant human endostatin on tumor cell IL-8 production are associated with increased endothelial cell apoptosis in an orthotopic model of human pancreatic cancer. Cancer Biol Ther. 2004:3:679-687. PMID: 15197351.
  102. Davis DW, Inoue K, Dinney CP, Hicklin DJ, Abbruzzese JL, McConkey DJ. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Res. 2004:64:4601-2610.
  103. Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L, McConkey DJ, Papageorgiou A, Munsell M, Philopena J, Engler H, Demers W, Maneval DC, Dinney CP, Connor RJ. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther. 2004:10:525-532.
  104. Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD. Phase ll study of the antiangiogenic agent SU5416 in patients with advance soft tissue sarcomas. Clin Cancer Res. 2004:10:5732-5740.
  105. Raut CP, Nawrocki S, Lashinger LM, Davis DW, Khanbolooki S, Xiong H, Ellis LM, McConkey DJ. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biol Ther. 2004:3:1217-1224.
  106. Carew JS, Nawrocki ST, Xu RH, Dunner K, McConkey DJ, Wierda WG, Keating MJ, Huang P. Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine. Leukemia. 2004:18:1934-1940. PMID: 15483672.
  107. Papageorgiou A, Lashinger L, Millikan R, Grossman HB, Benedict W, Dinney CP, McConkey DJ. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res. 2004:64:8973-8979. PMID: 15604261.
  108. Xiong HQ, Herbst R, Faria SC, Scholz C, Davis D, Jackson EF, Madden T, McConkey DJ, Hicks M, Hess K, Charnsangavej CA, Abbruzzese JL. A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs. 2004:22:459-466. PMID: 15292716.
  109. Zheng B, Georgakis GV, Li Y, Bharti A, McConkey DJ, Aggarwal BB, Younes A. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin's disease cell lines is independent of inhibitor of nuclear factor-kB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res. 2004:10:3207-3215. PMID: 15131062.
  110. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey DJ, Patel G, Guerciolini R, Wright J, Kantarjian H. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 2004:10:3371-3376. PMID: 15161691.
  111. Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, Abbruzzese JL, McConkey DJ. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res. 2004:10:33-42. PMID: 14734449.
  112. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther. 2004:3:59-70. PMID: 14749476.
  113. Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin Cancer Res. 2005:11:678-689. PMID: 15701856.
  114. Nutt LK, Gogvadze V, Uthaisang W, Mirnikjoo B, McConkey DJ, Orrenius S. Indirect effects of Bax and Bak initiate the mitochondrial alterations that lead to cytochrome c release during arsenic trioxide-induced apoptosis. Cancer Biol Ther. 2005:4:459-467. PMID: 15846091.
  115. Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP, McConkey DJ. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res. 2005:65:4902-4908. PMID: 15930312.
  116. Pino MS, Nawrocki ST, Cognetti F, Abruzzese JL, Xiong HQ, McConkey DJ. Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells. Cancer Biol Ther. 2005:4:1263-1269. PMID: 16319525.
  117. Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, Adam L. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res. 2005:65:10524-10535. PMID: 16288045.
  118. Nawrocki ST, Carew JS, Dunner K, Jr, Boise LH, Chiao PJ, Huang P, Abbruzzese JL, McConkey DJ. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res. 2005:65:11510-11519. PMID: 16357160.
  119. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K, Jr, Huang P, Abbruzzese JL, McConkey DJ. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res. 2005:65:11658-11666. PMID: 16357177.
  120. Carew JS, Nawrocki ST, Krupnik YV, Dunner K, Jr, McConkey DJ, Keating MJ, Huang P. Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood. 2006:107:222-231. PMCID: PMC1895341.
  121. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K, Jr, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 2006:66:3773-3781. PMID: 16585204.
  122. Pino MS, Shrader M, Baker CH, Cognetti F, Xiong HQ, Abbruzzese JL, McConkey DJ. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. Cancer Res. 2006:66:3802-3812. PMID: 16585207.
  123. Ruiz S, Krupnik Y, Keating M, Chandra J, Palladino M, McConkey DJ. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol Cancer Ther. 2006:5:1836-1843. PMID: 16891470.
  124. Canfield SE, Zhu K, Williams SA, McConkey DJ. Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol Cancer Ther. 2006:5:2043-2050. PMID: 16928825.
  125. Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, Bar-Eli M. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res. 2006:12:4671-4677. PMID: 16899617.
  126. Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R, Logsdon CD, Abbruzzese JL, McConkey DJ. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther. 2006:5:2251-2260. PMID: 16985059.
  127. Walterscheid JP, Nghiem DX, Kazimi N, Nutt LK, McConkey DJ, Norval M, Ullrich SE. Cis-urocanic acid, a sunlight-induced immunosuppressive factor, activates immune suppression via the 5-HT2A receptor. Proc Natl Acad Sci U S A. 2006:103:17420-17425. PMCID: PMC1859944.
  128. Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther. 2006:5:3032-3041. PMID: 17172406.
  129. Trevino JG, Gray MJ, Nawrocki ST, Summy JM, Lesslie DP, Evans DB, Sawyer TK, Shakespeare WC, Watowich SS, Chiao PJ, McConkey DJ, Gallick GE. Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells. Angiogenesis. 2006:9:101-110. PMID: 16871430.
  130. Zhang X, Yang Z, Dong L, Papageorgiou A, McConkey DJ, Benedict WF. Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects. Cancer Gene Ther. 2007:14:241-250. PMID: 17096027.
  131. Adam L, Black PC, Kassouf W, Eve B, McConkey DJ, Munsell MF, Benedict WF, Dinney CP. Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. J Urol. 2007:177(5):1900-1906. PMID: 17437845.
  132. Hariharan S, Gustafson D, Holden S, McConkey DJ, Davis D, Morrow M, Basche M, Gore L, Zang C, O'Bryant CL, Baron A, Gallemann D, Colevas D, Eckhardt SG. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol. 2007:18(8):1400-1407. PMID: 17693653.
  133. Kassouf W, Black PC, Tuziak T, Bondaruk J, Lee S, Brown GA, Adam L, Wei C, Baggerly K, Bar-Eli M, McConkey DJ, Czerniak B, Dinney CP. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol. 2008:179(1):353-358. PMCID: PMC2680144.
  134. Lee S, Jeong J, Majewski T, Scherer SE, Kim MS, Tuziak T, Tang KS, Baggerly K, Grossman HB, Zhou JH, Shen L, Bondaruk J, Ahmed SS, Samanta S, Spiess P, Wu X, Filipek S, McConkey DJ, Bar-Eli M, Issa JP, Benedict WF, Czerniak B. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. Proc Natl Acad Sci USA. 2007:104(34):13732-13737. PMCID: PMC1949496.
  135. Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, Dinney CP, McConkey DJ. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res. 2007:67(4):1430-1435. PMID: 17308080.
  136. Papageorgiou A, Dinney CP, McConkey DJ. Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Cancer Biol Ther. 2007:6(6):872-879. PMID: 17617740.
  137. Shrader M, Pino MS, Brown G, Black P, Adam L, Bar-Eli M, Dinney CP, McConkey DJ. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther. 2007:6(1):227-285. PMID: 17237287.
  138. Miller CP, Ban K, Dujka ME, McConkey DJ, Munsell M, Palladino M, Chandra J. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood. 2007:110(1):267-277. PMCID: PMC1896116.
  139. Majewski T, Lee S, Jeong J, Yoon D, Kram A, Kim M, Tuziak T, Bondaruk J, Lee S, Park W, Tang KS,Chung W, Shen L, Ahmed SS, Johnston DA, Grossman HB, Dinney CP, Zhou J, Harris RA, Snyder C, Filipek S, Narod SA, Watson P, Lynch HT, Gazdar A, Bar-Eli M, Wu XF, McConkey DJ, Baggerly K, Issa J, Benedict WF, Scherer SE, Czerniak B. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest. 2008:88(7):694-721. PMCID: PMC2849658.
  140. Zhou J, Zhang XQ, Ashoori F, McConkey DJ, Knowles MA, Dong L, Benedict WF. Early RB94-produced cytotoxicity in cancer cells is independent of caspase activation or 50 kb DNA fragmentation. Cancer Gene Ther. 2008:16(1):13-9. PMCID: PMC3090001.
  141. Pino MS, Balsamo M, Di Modugno F, Mottolese M, Alessio M, Melucci E, Milella M, McConkey DJ, Philippar U, Gertler FB, Natali PG, Nistico P. Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines. Clin Cancer Res. 2008:14(15):4943-50. PMCID: PMC2586967.
  142. Kassouf W, Brown GA, Black PC, Fisher MB, Inamoto T, Luongo T, Gallagher D, BAr-Eli M, McConkey DJ, Adam L, Dinney CP. Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer? J Urol. 2008:180(3):1146-53. PMID: 18639280.
  143. Nawrocki ST, Carew JS, Maclean KH, Courage JF, Huang P, Houghton JA, Cleveland JL, Giles FJ, McConkey DJ. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood. 2008:112(7):2917-26. PMCID: PMC2556625.
  144. Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Mejia PE, Sood AK, McConkey DJ, Logsdon CD. Nuclear factor-kappaB p65/reIA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res. 2008:14(24):8143-51. PMCID: PMC4403242.
  145. Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE,Bedikian AY, Camacho LH, Ross MI, Cormier JN, Gershenwald JE, Lee JE,Mansfield PF, Billings LA, Ng CS, Charnsangavej C, Bar-Eli M, Johnson MM, Murgo AJ, Prieto VG. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008:99(5):734-40. PMCID: PMC2528157.
  146. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ, Dinney CP. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res. 2008:14(5):1478-86. PMID:18316572.
  147. Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G, Zhu QS, Bornmann WG, McConkey DJ, Pollock RE, Lev DC. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res. 2009:15(10):3472-3483. PMID: 19417021.
  148. Fisher M, Zhang X-Q, McConkey DJ, Benedict WF. Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon cx: possible use as a surrogate marker. Cancer Gene Therapy. 2009:16(7):567-72. PMCID: PMC3891523.
  149. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey DJ, Bar-Eli M, Dinney C. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res. 2009:15(16):5060-5072. e-Pub 2009. PMID: 19671845.
  150. Zhu K, Chan W, Heymach J, Wilkinson M, McConkey DJ. Control of HlF-1alpha expression by elF2 alpha phosphorylation-mediated translational repression. Cancer Res. 2009:69(5):1836-1843. PMCID: PMC4188393.
  151. Haddad Y, Choi W, McConkey DJ. Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res. 2009:15(2):532-42. PMCID: PMC2729136.
  152. Raut CP, Takamori RK, Davis DW, Sweeney-Gotsch B, O'Reilly MS, McConkey DJ. Direct effects of recombinant human endostatin on tumor cell lL-8 production are associated with increased endothelial cell apoptosis in an orthotopic model of human pancreatic cancer. Cancer Biol Ther. 2009:8(10).
  153. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ, Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009:69(14):5820-5828. PMCID: PMC4378690.
  154. Zhu K, Dunner K, McConkey DJ. Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene. 2010:29(3):451-62. PMCID: PMC2809784.
  155. Svatek RS, Shah JB, Xing J, Chang D, Lin J, McConkey DJ, Wu X, Dinney CP. A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. Cancer. 2010:116(19):4513-4519. e-Pub 6/2010. PMID: 20572047.
  156. Metwalli AR, Khanbolooki S, Jinesh G, Shah JB, Shrader M, Choi W, Lashinger LM, Chunduru S, McConkey DJ, McKinlay M, Kamat AM. Smac mimetic reverses resistance to TRAIL and chemotherapy in human cancer cells. Cancer Biol Ther. 2010:10(9):885-92. e-Pub 11/2010. PMCID: PMC3230293.
  157. Black PC, Shetty A, Brown GA, Esparza-Coss E, Metwalli AR, Agarwal PK, McConkey DJ Hazle JD, Dinney CP. Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis. BJU Int. 2010:106(11):1799-1804. PMID: 20500508.
  158. Black PC, Brown GA, Dinney CP, Kassouf W, Inamoto T, Arora A, Gallagher D, Munsell MF, Bar-Eli M, McConkey DJ, Adam L. Receptor heterodimerization: A new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. J Urol. 2011:185(2):693-700. PMID: 21168861.
  159. Chiong E, Lee IL, Dadbin A, Sabichi AL, Harris LD, Urbauer DL, McConkey DJ, Dickstein RJ, Cheng T, Grossman HB. Effects of mTOR inhibitor everolimus (RAD001) bladder cancer cells. Clin Can Res. 2011:17(9). e-Pub 3/2011. PMCID: PMC4272218.
  160. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One. 2011:6(6):e20636. PMCID: PMC3113804.
  161. Kim MP, Truty MJ, Choi W, Kang Y, Chopin-Lally X, Gallick GE, Wang H, McConkey DJ, Hwang R, Logsdon C, Abbruzzesse J, Fleming JB. Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Ann Surg Oncol. 2012:19(3):395-403. e-Pub 6/2011. PMCID: PMC4112459.
  162. Santos FP, Kantarjian H, McConkey DJ, O'Brien S, Faderi S, Borthakur G, Ferrajoli A, Wright J, Cortes J. Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase. Clin Lymphoma Myeloma Leuk. 2011:11(4):355-360. PMCID: PMC4405186.
  163. Liu H, Zhang T, Chen R, McConkey DJ, Ward JF, Curley SA. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG. J Surg Res. 2012:176(1):147-53. e-Pub 10/2011. PMID: 22099584.
  164. Lopez G, Torres K, Liu J, Hernandez B, Young E, Belousov R, Bolshakova S, Lazar A, Slopis JM, McCutcheon IE, McConkey DJ, Lev DC. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res. 2011:71(1):185-196. e-Pub 11/2011. PMCID: PMC3064267.
  165. Millward M, Price T, Townsend A, Sweeney C, Spencer A, Sukumaran S, Longenecker A, Lee L, Lay A, Sharma G, Gemmil RM, Drabkin HA, Lloyd GK, Neuteboom ST, McConkey DJ, Palladino MA, Spear MA. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs. 2012:30(6):2303-17. e-Pub 11/2011. PMID: 22080430.
  166. Ni CT, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore VG, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, McConkey DJ, Sallan SE, Silverman L, Hirsch MS, Carrasco DR, Letai A. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011:334(6059):1129-1133. PMCID: PMC3280949.
  167. Choi W, Shah JB, Tran M, Svatek R, Marquis L, Lee IL, Yu D, Adam L, Wen S, Shen Y, Dinney C, McConkey DJ, Siefker-Radtke A. P63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One. 2012:7(1):e30206. PMCID: PMC3254658.
  168. Marquis L, Tran M, Choi W, Lee IL, Huszar D, Siefker-Radtke A, Dinney C, McConkey DJ. P63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells. Cancer Biol Ther. 2012:13(7):477-86. PMCID: PMC3958424.
  169. Liu H, Zhang T, Chen R, McConkey DJ, Ward JF, Curley SA. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG. J Surg Res. 2012:176(1):147-53. PMID: 22099584.
  170. Braeuer RR, Zigler M, Dobroff AS, Huang L, Choi W, McConkey DJ, Shoshan E, Mobley AK, Song R, Raz A, Bar-Eli M. 2014. Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res. 2012:72(22):5757-5766. PMCID: PMC3500452.
  171. Tran MN, Choi W, Wszolek MF, Navai N, Lee IL, Nitti G, Wen S, Flores ER, Siefker-Radtke A, Czerniak B, Dinney C, Barton M, McConkey DJ. The p63 protein isoform DNp63a inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. J Biol Chem. 2013:288(5):3275-88. e-Pub 12/2012. PMCID: PMC3561548.
  172. Lee EK, Jinesh GG, Laing NM, Choi W, McConkey DJ, Kamat AM. A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin. Cancer Biol Ther. 2013:14(9):812-22. PMCID: PMC3909550.
  173. Gust KM, McConkey DJ, Awrey S, Hegarty PK, Qing J, Bondaruk J, Ashkenazi A, Czerniak B, Dinney CP, Black PC. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol Cancer Ther. 2013:12(7):1245-54. e-Pub 5/2013. PMCID: PMC3707970.
  174. Jäger W, Horiguchi Y, Shah J, Hayashi T, Awrey S, Gust KM, Hadaschik BA, Matsui Y, Anderson S, Bell RH, Ettinger S, So AI, Gleave ME, Lee IL, Dinney CP, Tachibana M, McConkey DJ, Black PC. Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa. J Urol. 2013:190(4):1404-9. e-Pub 3/2013. PMCID: PMC3805942.
  175. Cheng T, Roth B, Choi W, Black PC, Dinney C, McConkey DJ. Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting. PLoS One. 2013:8(2):e57284. e-Pub 2/2013. PMCID: PMC3582560.
  176. Qi W, White MC, Choi W, Guo C, Dinney C, McConkey DJ, Siefker-Radtke A. Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells. PLoS One. 2013:8(7):e69509. e-Pub 7/2013. PMCID: PMC3715471.
  177. Dickstein RJ, Nitt G, Dinney CP, Davies BR, Kamat A, McConkey DJ. Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. Cancer Biol Ther. 2012:13(13):1325-38. PMCID: PMC3493441.
  178. The Cancer Genome Atlas research network contributed collectively to this study: Weinstein JN, Akbani R, Broom BM, Wang W, …McConkey DJ…. Comprehensive molecular characterization of urothelial carcinoma of the bladder. Nature. 2014:507(7492):315-22. PMCID: PMC3962515.
  179. Choi W, Porten S, Kim SH, Roth B, Cheng T, Willis D, Tran MN, Lee IL, Melquist J, Bondaruk JE, McConkey DJ. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014:25(2):152-65. PMCID: PMC4011497.
  180. McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Milikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. A prognostic gene expression signature in the molecular classification of chemotherapy-naïve urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: A phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Urol. 2016:69(5):855-62. PMCID: PMC4775435.
  181. Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, McConkey DJ, Miller VA, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasiv bladder cancer. Eur Urol. 2015:68(6):959-67. e-Pub ahead of print. PMCID: PMC4764095.
  182. Guo CC, Dadhania V, Zhang L, Majewski , Bondaruk J, Sykulski M, Wronowska W, Gambin A, Wang Y, Zhang S, Fuentes-Mattei E, Kamat AM, Dinney C, Siefker-Radtke A, Choi W, Baggerly KA, McConkey D, Weinstein JN, Czerniak B. Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer.  Eur. Urol. 2016. e-Pub ahead of print. PMID: 26988609.

Book Chapters, Monographs

  1. Orrenius S, McConkey DJ, Nicotera P. Mechanisms of cell toxicity - The thiol/calcium hypothesis. In: Calcium-dependent Processes in the Liver. MTP Press, Ltd. 1988:181-189.
  2. Orrenius S, Thor H, McConkey DJ, Nicotera P, Bellomo G. Mechanisms of cell toxicity. The thiol/calcium hypothesis. In: Microsomes and Drug Oxidations. Taylor & Francis. 1988:329-337.
  3. Orrenius S, McConkey DJ, Nicotera P. Mechanisms of oxidant-induced cell damage. In: Oxy- radicals in Molecular Biology and Pathology. Alan R. Liss. 1988:327-339.
  4. McConkey DJ, Orrenius S. The role of calcium in free radical-induced cell damage. In: Free Radicals: Methodology and Concepts. Richelieu Press. 1988:419-428.
  5. Orrenius S, Thor H, McConkey DJ, Nicotera P, Bellomo G. 7.2 molecular mechanisms of cell toxicity. In: Molecular Aspects of Human Disease. Ellis Horwood, Ltd. 1989:68-75.
  6. McConkey DJ, Orrenius S. Biochemical mechanisms of cell toxicity: The role of a Ca2+ activated endonuclease. In: Xenobiotic Metabolism and Disposition. Taylor & Francis. 1989:367-373.
  7. Orrenius S, Thor H, McConkey DJ, Nicotera P, Bellomo G. Molecular mechanisms of cell toxicity. In: The Molecular Biology of Human Diseases. Ellin Horwood Publishers. 1989:316-323.
  8. Orrenius S, McConkey DJ, Nicotera P. On the role of calcium in oxidative cell injury. In: Cell Calcium Metabolism. Plenum Press. 1989:451-461.
  9. Nicotera P, McConkey DJ, Dypbukt-Kallman JM, Jones DP, Orrenius S. Role of Ca2+ activated catabolic processes in cell killing. In: Free Radicals in the Pathogenesis of Liver Injury. 76. Pergamon Press, 1989:37-43.
  10. McConkey DJ, Orrenius S. Cellular signaling in thymocyte apoptosis. In: Apoptosis: The Molecular Basis of Cell Death. Cold Spring Harbor Press. 1991:227-246.
  11. McConkey DJ, Aw TY, Orrenius S. Role of Ca2+-mediated endonuclease activation in chemical toxicity. In: Molecular Aspects of Human Disease. Ellis Horwood, Ltd. 1991:68-75.
  12. McConkey DJ, Aw TY, Orrenius S. Role of Ca2+ mediated endonuclease activation in chemical toxicity. In: Tissue-specific Toxicity: Biochemical Mechanisms. Academic Press Ltd. 1992:1-14.
  13. McConkey DJ, Jondal M, Orrenius S. The role of calcium in the regulation of apoptosis. European School of Hematology. In: Apoptosis or Programmed Cell Death: From Basic Research to Clinical Applications. ESM Press. 1993.
  14. McConkey DJ, McDonnell TJ. Analysis of chromatin cleavage in apoptotic cells. In: The Handbook of Experimental Immunology. Blackwell Science. 1994.
  15. McConkey DJ. Calcium flux measurement in cell death. In: Techniques in Apoptosis: A User's Guide. Portland Press. 1994.
  16. McConkey DJ. Cellular signaling in cell death. In: Textbook of Critical Care. W.B. Saunders. 1994:147-153.
  17. McConkey DJ, Jondal M, Orrenius S. Chemical induced apoptosis in the immune system. In: Immunotoxicology and Immunopharmacology. Raven Press. 1994:473-485.
  18. McConkey DJ, Orrenius S, Jondal M. Signal transduction in thymocyte apoptosis. In: Cell Death: The cellular and molecular biology of apoptosis. Harwood Academic Publishers. 1994:19-30.
  19. McConkey DJ, Bold RJ. Cellular signaling and cell death. In: Textbook of Critical Care. W.B. Saunders. 1999:586-596.
  20. McConkey DJ, Orrenius S. Programmed cell death. In: Frontiers in Biology. Istituto della Enciclopedia Italiana. 1999:553-571.
  21. McConkey DJ, Harbison M, Orrenius S. Calcium regulation of apoptosis. In: Carafoli and Klee, Calcium as a Cellular Regulator. Oxford University Press. 1999.
  22. McConkey DJ, Davis D. The ATP switch in apoptosis. In: Mitochondria in Pathogenesis. Lemasters and Nieminen, Eds. Springer. 2001.
  23. Nutt L, McConkey DJ. Measurement of changes in intracellular calcium. In: Apoptosis Methods and Protocols. Humana Press. 2004.
  24. Williams SA, McConkey DJ. Proteasome inhibition and apoptosis. In: Cancer Drug Discovery and Development: Proteasome Inhibitors in Cancer Therapy. Julian Adams, Ed. Humana Press, Inc. 2004.
  25. Wu, XR, Sun, TT, McConkey DJ, Shrader, M, Papageorgiou, A.  Animal models of bladder cancer.  Textbook of bladder cancer. 2006:157-169.
  26. McConkey DJ.  Apoptosis signaling pathways in pancreatic cancer.  In: Pancreatic cancer. Neoptolemos, Urrutia, Abbruzzese, and Buchler, Eds. Springer. 2010.
  27. McConkey DJ.  Molecular characterization of pancreatic cancer cell lines.  In: Pancreatic cancer.  Neoptolemos, Urrutia, Abbruzzese, and Buchler, Eds. Springer. 2010.
  28. Chan, KS and McConkey DJ.  Cancer stem cells and intrinsic subtypes in bladder cancer.  In: Bladder cancer: diagnosis and clinical management. Lerner, Schoenberg, and Sternberg, Eds. Wylie. 2015.



Institutional Administrative Appointments

1/1999-1/2004 Faculty Senate, Member.
1/1999-present Internal Advisory Committee, AML P01 (PI: Andreeff), Member.
1/2000-1/2003 Executive Committee of the Faculty Senate, Member.
1/2000-1/2003 Experimental Therapeutics Advisory Committee, Member
1/2001-1/2005 Conflict of Interest Committee, Member.
1/2001-present UTMDACC CTDP Study Section, Member.
2001-present     Executive Committee, Bladder Cancer SPORE, Member.
1/2002-1/2005 Research Laboratory Space Subcommittee, Member.
1/2003-1/2004 Department of Urology Chairman Search Committee, Member.
2004-2008Executive Committee, Pancreatic Cancer SPORE, Member.
1/2008 Postdoctoral Advisory Committee, Member.
1/2008Executive Committee of the Science Faculty, Member.
1/2008Internal Advisory Committee, Lymphoma SPORE (PI: Younes), Member.
2012-2014  Institutional Research Executive Committee, Member.

Professional Societies

1993-presentAmerican Association for Cancer Research
1993-2003Gulf Coast Society of Toxicology
1993-2004 Society of Toxicology
1993-2005 American Association of Immunologists
1993-2005American Society of Hematology
2007-presentAmerican Urological Society
2007-presentSociety of Basic Urological Research, Houston, TX
2007-presentSociety of Urologic Oncology
2008-presentAmerican Society of Clinical Oncology Member

Awards & Honors

1986-1986American Scandinavian Foundation Fellowship
1991-1993Cancer Research Institute Fellowship
2001-2003HSC Honors Convocation Recipient
2001-2001John P. McGowen Outstanding Teacher Award, University of Texas Health Science Center, GSBS
2002-2002Educator of the Month, M. D. Anderson Cancer Center
2003-2003Award for Research Excellence, UT M.D. Anderson Cancer Center
2003-2003Finalist, Julie and Ben Rogers Award for Excellence
2013-present Reappointed to GSBS Faculty with Highest Commendation
2014-presentRobert F. Fly Professorship of Surgical Oncology
2016-2016Sowell-Huggins Professor and Fellow in Cancer Research